Brief: Heat Biologics Provides Data From Phase 2 Study Investigating Hs-110 In Combination With BMY's Nivolumab

Scorpius Holdings

03/06/2019 14:14

June 3 (Reuters) - Heat Biologics Inc  HTBX.O :
    * HEAT BIOLOGICS - PROVIDES DATA FROM ONGOING PHASE 2 STUDY
INVESTIGATING HS-110 IN COMBINATION WITH BMY'S ANTI-PD-1
CHECKPOINT INHIBITOR, NIVOLUMAB
    * HEAT BIOLOGICS INC - UPDATED RESULTS WERE OBTAINED FROM
COHORT B
PATIENTS WHOSE DATA HAS MATURED AN ADDITIONAL 3 MONTHS SINCE
LAST REPORTED
    * HEAT BIOLOGICS INC - ANNOUNCES DATA SUGGESTING THAT HS-110
PLUS
NIVOLUMAB MAY RESTORE CLINICAL BENEFIT AFTER CHECKPOINT
INHIBITOR TREATMENT FAILURE
    * HEAT BIOLOGICS INC - CLINICAL BENEFIT OBSERVED IN 55% OF
PATIENTS RECEIVING HS-110 PLUS NIVOLUMAB AFTER CHECKPOINT
INHIBITOR TREATMENT FAILURE
    * HEAT BIOLOGICS - HS-110 IN COMBINATION WITH NIVOLUMAB
DEMONSTRATES CLINICAL ACTIVITY IN LOW CD8+ TIL 'COLD TUMOR'
PATIENTS AND PD-L1 NEGATIVE TUMORS
    * HEAT BIOLOGICS INC - OCCURRENCE OF DERMAL INJECTION SITE
REACTIONS IS ASSOCIATED WITH IMPROVED PROGRESSION FREE SURVIVAL
AND OVERALL SURVIVAL
    * HEAT BIOLOGICS INC - TREATMENT WITH HS-110 IN COMBINATION
WITH
NIVOLUMAB WAS WELL TOLERATED

Source text: (https://bit.ly/2QDjHxs)
Further company coverage:  BMY.N 

 ((Reuters.Briefs@thomsonreuters.com;))